Lihong Weng
YOU?
Author Swipe
View article: Potential of Fibulin2 as a therapeutic target against cancer and as a diagnostic marker (Review)
Potential of Fibulin2 as a therapeutic target against cancer and as a diagnostic marker (Review) Open
Cancers are not merely composed of tumor cells; rather, they constitute a complex tumor microenvironment (TME) comprising diverse cell types and noncellular factors. Extracellular matrix (ECM) represents a critical component of the TME. Fi…
View article: Risk factors for dysphagia in elderly patients with COPD: a systematic review and meta-analysis protocol
Risk factors for dysphagia in elderly patients with COPD: a systematic review and meta-analysis protocol Open
Introduction Given the global trend toward population ageing, chronic obstructive pulmonary disease (COPD) has emerged as an increasingly common health concern. As a chronic pulmonary disorder frequently encountered in clinical settings, C…
View article: Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients
Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients Open
Background Chimeric antigen receptor- (CAR) T cell therapy has dramatically improved outcomes in patients with relapsed/refractory multiple myeloma (RRMM) and is being evaluated in newly diagnosed multiple myeloma (NDMM) patients. Long-ter…
View article: Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure
Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure Open
Treatment options for epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) failure are limited, and platinum-based chemotherapy remains the main treatment. The…
View article: B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma Open
Importance Patients with high-risk newly diagnosed multiple myeloma (NDMM) often have poor outcomes with standard treatments, necessitating novel effective frontline therapies to enhance clinical outcomes. GC012F, a B-cell maturation antig…
View article: Integration of bioinformatics analysis reveals ZNF248 as a potential prognostic and immunotherapeutic biomarker for LIHC: machine learning and experimental evidence
Integration of bioinformatics analysis reveals ZNF248 as a potential prognostic and immunotherapeutic biomarker for LIHC: machine learning and experimental evidence Open
Liver hepatocellular carcinoma (LIHC) is a major contributor to cancer-related mortality worldwide, posing substantial diagnostic and therapeutic challenges. Although zinc finger proteins (ZNFs) are known to play a role in LIHC, the specif…
View article: Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFRmutantAdvanced NSCLC Beyond Limited Progression on Osimertinib
Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFRmutantAdvanced NSCLC Beyond Limited Progression on Osimertinib Open
Background: Treatment options for advanced non-small-cell lung cancer (NSCLC) after osimertinib failure are limited, and osimertinib continuation is recommended for selected patients. Metronomic oral vinorelbine is an effective treatment w…
View article: P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: GC012F is a B cell maturation antigen (BCMA) and CD19 dual-targeting chimeric antigen receptor (CAR)-T cell developed on the novel FasTCAR-T platform enabling 22-3…
View article: S234: UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
S234: UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA Open
Background: CD19-directed CAR-T cell therapy has been demonstrated to be a valuable treatment option for relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL). It has been shown that 39% to 97% of clinical B-NHL samples also expres…
View article: Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than those without CNS involvement, and patients currently have limited treatment options. T cells genetically engineered with CD19-targeted chimeric antigen …
View article: Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than those without CNS involvement, and patients currently have limited treatment options. T cells genetically engineered with CD19-targeted chimeric antigen …
View article: Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Supplementary Figures and Legends
View article: Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Open
Supplementary Figures and Legends
View article: Supplementary Figure S4 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma
Supplementary Figure S4 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma Open
Supplementary Figure S4. 18F-Fluorodeoxyglucose ( F-FDG)-CT/PET of subjects UPN031 and UPN033
View article: Supplemental Table 3 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Supplemental Table 3 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma Open
Down-regulated genes
View article: Supplemental Table 3 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Supplemental Table 3 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma Open
Down-regulated genes
View article: Supplementary Figure S2 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma
Supplementary Figure S2 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma Open
Supplementary Figure S2. Consort flow diagram.
View article: Supplemental Table 1 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Supplemental Table 1 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma Open
Taqman probes used in qPCR
View article: Supplementary Figure S4 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma
Supplementary Figure S4 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma Open
Supplementary Figure S4. 18F-Fluorodeoxyglucose ( F-FDG)-CT/PET of subjects UPN031 and UPN033
View article: Supplemental Figures from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Supplemental Figures from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma Open
Supplemental Figure 1. High dose CS1 CAR T cells were not able to prevent tumor relapse Supplemental Figure 2. Soluble CS1 does not interfere with CS1 CAR function Supplemental Figure 3. Lenalidomide preferentially expanded CD8+CAR+ T cell…
View article: Supplementary Figure S3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma
Supplementary Figure S3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma Open
Supplementary Figure S3. Treatment regimens for each patient, with relapse designated day 0.
View article: Supplementary Figure S3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma
Supplementary Figure S3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma Open
Supplementary Figure S3. Treatment regimens for each patient, with relapse designated day 0.
View article: Supplemental Table 4 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Supplemental Table 4 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma Open
DAVID Functional annotation analysis
View article: Data from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Data from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma Open
Purpose: Multiple myeloma remains an incurable malignancy of plasma cells despite considerable advances in treatment. The purpose of the study was to develop novel chimeric antigen receptors (CAR) for the treatment of multiple myeloma and …
View article: Supplementary methods from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma
Supplementary methods from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma Open
Supplementary methods. These are more detailed methods than can be included in the body of the article.
View article: Supplementary Figure S5 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma
Supplementary Figure S5 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma Open
Supplementary Figure S5. T cell detection in tumor tissue from UPN031.
View article: Supplementary Figure S1 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma
Supplementary Figure S1 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8<sup>+</sup> T Cells in Patients with Recurrent Glioblastoma Open
Supplementary Figure S1. Catheter position with respect to resection site.
View article: Supplemental Table 2 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Supplemental Table 2 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma Open
Up-regulated genes